Novo Nordisk A/S. Daily Stock Analysis

Daily Stock Analysis, NVO, Novo Nordisk A/S, priceseries

Novo Nordisk A/S. Daily Stock Analysis
Stock Information
Open
102.73
Close
100.85
High
103.17
Low
100.67
Previous Close
104.11
Daily Price Gain
-3.26
YTD High
109.72
YTD High Date
Jan 3, 2022
YTD Low
91.51
YTD Low Date
Jan 24, 2022
YTD Price Change
-7.94
YTD Gain
-7.30%
52 Week High
117.35
52 Week High Date
Dec 16, 2021
52 Week Low
65.52
52 Week Low Date
Mar 25, 2021
52 Week Price Change
33.35
52 Week Gain
49.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 24. 2017
33.36
May 17. 2017
36.73
17 Trading Days
10.11%
Link
LONG
Dec 22. 2017
49.12
Jan 30. 2018
52.34
24 Trading Days
6.57%
Link
LONG
Jul 2. 2018
43.51
Jul 31. 2018
46.76
20 Trading Days
7.46%
Link
LONG
Jun 5. 2019
46.27
Jun 20. 2019
48.71
11 Trading Days
5.26%
Link
LONG
Oct 23. 2019
51.34
Nov 18. 2019
54.36
18 Trading Days
5.88%
Link
LONG
Mar 26. 2020
54.47
Apr 13. 2020
57.31
11 Trading Days
5.22%
Link
LONG
Apr 14. 2020
58.18
Apr 29. 2020
61.18
11 Trading Days
5.17%
Link
LONG
Apr 8. 2021
68.88
May 27. 2021
79.09
35 Trading Days
14.82%
Link
LONG
Jul 1. 2021
83.97
Aug 24. 2021
103.72
37 Trading Days
23.52%
Link
LONG
Oct 15. 2021
102.34
Nov 22. 2021
112.87
26 Trading Days
10.29%
Link
Company Information
Stock Symbol
NVO
Exchange
NYSE
Company URL
http://www.novonordisk.com
Company Phone
4544448888
CEO
Lars Fruergaard Jørgensen
Headquarters
-
Business Address
NOVO ALLE DK 2880, BAGSVAERD DENMARK, DENMARK 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Other
CIK
0000353278
About

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharmaceuticals segments. The Diabetes and Obesity Care segment covers insulins, glucagon-like-peptide 1, other protein-related products, oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment involves in the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation, and therapy areas. The company was founded by August Krogh, Marie Krogh, Hans Christian Hagedorn, August Kongsted, Harald Pedersen, and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Description

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading